ErbB2 Program

About Cogent Biosciences

Cogent Biosciences is a publicly traded biotech firm dedicated to designing and developing best-in-class precision therapies for genetically driven diseases, with a core focus on oncology. Its most advanced program, bezuclastinib, has an FDA New Drug Application accepted with a PDUFA date of December 30, 2026, for Non-Advanced Systemic Mastocytosis (NonAdvSM). The company's strategy integrates deep expertise in structural biology, enzymology, and translational science to rationally target well-validated mutations, aiming to improve upon existing therapies with known limitations. Cogent's robust pipeline extends beyond its lead asset into other high-value genetic targets, including FGFR2, ErbB2, and PI3Kα.

Therapeutic Areas